Company: TYRA
Filing Date: 2025-05-08
Form Type: S-3
Source: 0001193125-25-116008
Chunk: 55

Company: Tyra Biosciences, Inc.
Filing Date: 2025-05-08
Form: S-3
Chunk 55
---
 of our common stock on our behalf, TD Cowen will be deemed to be an “underwriter” within the meaning of
the Securities Act, and the compensation paid to TD Cowen will be deemed to be underwriting commissions or discounts. We have agreed in the Sales Agreement to provide indemnification and contribution to TD Cowen against certain liabilities,
including liabilities under the Securities Act. As sales agent, TD Cowen will not engage in any transactions to stabilize our common stock.

13

Our common stock is listed on the Nasdaq Global Select Market and trades under the symbol
“TYRA.” The transfer agent of our common stock is Computershare Trust Company, N.A.

TD Cowen and/or its affiliates have
provided, and may in the future provide, various investment banking and other financial services for us for which services they have received and, may in the future receive, customary fees.

14

LEGAL MATTERS

Latham & Watkins LLP, San Diego, California, will pass upon certain legal matters relating to the issuance and sale of the securities offered hereby
on behalf of Tyra Biosciences, Inc. Latham & Watkins LLP and certain attorneys in the firm who have rendered, and will continue to render, legal services to us, own shares of our common stock representing in the aggregate less than one
percent of the shares of our common stock outstanding. TD Securities (USA) LLC is being represented in connection with this offering by Cooley LLP, New York, New York.

EXPERTS

Ernst & Young LLP, independent registered public accounting firm, has audited our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are
incorporated by reference in reliance on Ernst & Young LLP’s report, given on their authority as experts in accounting and auditing.

15

$150,000,000

Common Stock

PROSPECTUS

TD Cowen

, 2025

PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution The following is an estimate of the expenses (all of which are to be paid by the registrant) that we may incur in connection with the securities being registered hereby. Each item listed is estimated, except for the SEC registration fee.

| SEC registration fee                         |     | $ | 59,390 | -1